| Description | KD-026 (SLx 4090), a microsomal triglyceride transfer protein (MTP) inhibitor(IC50 = 8.0 nM), is used in type 2 diabetes studies. |
| In vitro | KD-026 对载脂蛋白B显示出抑制作用（IC50 = 9.6 nM），但对Caco-2细胞中载脂蛋白A1的分泌无影响[1]。 |
| In vivo | 在大鼠中，KD-026（30 mg/kg）通过降低50%的餐后脂肪（ED50 = 7 mg/kg）[1]。 |
| Target activity | ApoB:9.6 nM, MTP:8.0 nM |
| Synonyms | SLx 4090, SLx4090, KD026, SLx-4090 |
| molecular weight | 546.54 |
| Molecular formula | C31H25F3N2O4 |
| CAS | 913541-47-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/ml (100.63 mM) |
| References | 1. Enoch Kim, et al. A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther. 2011 Jun;337(3):775-85. |